Drug intelligence / Profile preview

CTB-05

Development stage: Preclinical
Lead developer: Beijing Percans Oncology
Modality: Small Molecules

Overview

CTB-05 is a small molecule therapeutic candidate currently in preclinical development by Beijing Percans Oncology. It is being investigated for the treatment of rare and aggressive renal malignancies, specifically Clear Cell Sarcoma of the Kidney (CCSK) and Renal Cell Carcinoma (RCC). As a pipeline asset from Beijing Percans Oncology, a biotechnology company focused on oncology and rare diseases, CTB-05 represents a targeted approach to kidney cancer, although its specific molecular target and mechanism of action have not yet been publicly disclosed. The drug is part of a broader effort to develop novel therapies for pediatric and adult renal cancers with high unmet medical needs.

Beyond the preview

Go deeper on CTB-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTB-05.

Explore the full profile